USD 0.38
(-3.43%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -1.60 USD | 19.19% |
2022 | -1.98 USD | -50.0% |
2021 | -1.32 USD | 45.9% |
2020 | -2.44 USD | 15.57% |
2019 | -2.89 USD | 37.45% |
2018 | -4.62 USD | 28.81% |
2017 | -6.49 USD | 17.53% |
2016 | -7.87 USD | 8.17% |
2015 | -8.57 USD | -13.51% |
2014 | -7.55 USD | -6.79% |
2013 | -7.07 USD | 64.98% |
2012 | -13.03 USD | 0.0% |
2010 | -0.04 USD | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q1 | -0.23 USD | 23.33% |
2023 Q3 | -0.40 USD | 13.04% |
2023 Q1 | -0.46 USD | 42.5% |
2023 Q2 | -0.46 USD | 0.0% |
2023 FY | - USD | 19.19% |
2023 Q4 | -0.30 USD | 25.0% |
2022 FY | - USD | -50.0% |
2022 Q4 | -0.80 USD | -122.22% |
2022 Q3 | -0.36 USD | 2.7% |
2022 Q2 | -0.37 USD | 0.0% |
2022 Q1 | -0.37 USD | -68.18% |
2021 Q1 | -0.29 USD | 27.5% |
2021 Q2 | -0.40 USD | -37.93% |
2021 FY | - USD | 45.9% |
2021 Q4 | -0.22 USD | 45.0% |
2021 Q3 | -0.40 USD | 0.0% |
2020 Q1 | -0.42 USD | 0.0% |
2020 Q4 | -0.40 USD | -8.11% |
2020 Q2 | -1.36 USD | -223.81% |
2020 FY | - USD | 15.57% |
2020 Q3 | -0.37 USD | 72.79% |
2019 Q2 | -0.97 USD | 3.0% |
2019 FY | - USD | 37.45% |
2019 Q4 | -0.42 USD | 19.23% |
2019 Q3 | -0.52 USD | 46.39% |
2019 Q1 | -1.00 USD | 9.09% |
2018 Q1 | -1.33 USD | 1.48% |
2018 FY | - USD | 28.81% |
2018 Q4 | -1.10 USD | 0.0% |
2018 Q3 | -1.10 USD | -7.84% |
2018 Q2 | -1.02 USD | 23.31% |
2017 Q2 | -1.78 USD | 7.77% |
2017 Q1 | -1.93 USD | 5.39% |
2017 Q4 | -1.35 USD | 6.9% |
2017 FY | - USD | 17.53% |
2017 Q3 | -1.45 USD | 18.54% |
2016 Q2 | -2.03 USD | -6.84% |
2016 Q4 | -2.04 USD | -7.94% |
2016 FY | - USD | 8.17% |
2016 Q1 | -1.90 USD | -4.97% |
2016 Q3 | -1.89 USD | 6.9% |
2015 FY | - USD | -13.51% |
2015 Q4 | -1.81 USD | 19.91% |
2015 Q3 | -2.26 USD | 7.38% |
2015 Q2 | -2.44 USD | -19.02% |
2015 Q1 | -2.05 USD | -6.22% |
2014 Q1 | -1.64 USD | 2.38% |
2014 FY | - USD | -6.79% |
2014 Q4 | -1.93 USD | -10.92% |
2014 Q3 | -1.74 USD | 22.32% |
2014 Q2 | -2.24 USD | -36.59% |
2013 FY | - USD | 64.98% |
2013 Q2 | -2.86 USD | -146.55% |
2013 Q1 | -1.16 USD | 77.82% |
2013 Q4 | -1.68 USD | -24.44% |
2013 Q3 | -1.35 USD | 52.8% |
2012 Q1 | -16.45 USD | 29.91% |
2012 Q2 | 17.40 USD | 205.78% |
2012 Q3 | -4.34 USD | -124.94% |
2012 Q4 | -5.23 USD | -20.51% |
2012 FY | - USD | 0.0% |
2011 Q2 | -0.01 USD | 66.32% |
2011 Q1 | -0.02 USD | -206.35% |
2011 Q3 | -0.01 USD | -86.15% |
2011 Q4 | -23.47 USD | -193866.94% |
2010 Q2 | -0.01 USD | 0.0% |
2010 Q3 | -0.01 USD | -22.22% |
2010 Q4 | -0.01 USD | 28.41% |
2010 FY | - USD | 0.0% |
2009 Q4 | -0.01 USD | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
Xeris Biopharma Holdings, Inc. | -0.45 USD | -255.556% |
Arrowhead Pharmaceuticals, Inc. | -1.91 USD | 16.23% |
Codexis, Inc. | -1.12 USD | -42.857% |
Viridian Therapeutics, Inc. | -5.31 USD | 69.868% |